Invited Speaker Presentation International Celiac Disease Symposium 2026

What are the Optimal Endpoints to Register a Celiac Drug? A Regulatory Perspective (#140)

Irena Lavine 1 , Melissa Shapiro 1
  1. U.S. Food & Drug Administration, Silver Spring, MD, United States
Publish consent withheld